WebONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARC-IM and ARC-EX. The company’s first FDA pivotal trial, called Up-LIFT, commenced in January 2024 with plans to enroll 65 subjects at up to 15 centers worldwide. ONWARD is headquartered at the High Tech Campus in Eindhoven, the … Web8 de jun. de 2024 · ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARC IM and ARC EX. The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2024 with 65 subjects worldwide. The company completed first-in-human use of its ARC IM neurostimulator in May 2024.

ONWARD raises USD 32M to further develop and commercialize their ARC ...

WebONWARD, Eindhoven, Noord-Brabant. 613 likes · 73 talking about this. ONWARD is a medical technology company creating innovative therapies for spinal cord... Web30 de jun. de 2024 · ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARC IM and ARC EX. The company’s first FDA pivotal trial, … greenidge crypto mining

Swiss-Dutch startup Onward raises €26.5M to enable …

WebHá 2 dias · ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord … Web22 de abr. de 2024 · Medical technology company ONWARD has raised $32m funding for the development and commercialisation of its ARC Therapy. The financing round was led … Web30 de set. de 2024 · It is also beginning to expand in the United States, in Massachusetts. Onward’s therapy is based on two devices, one implantable (ARC-IM) and one external (ARC-EX), each targeting different levels of spinal cord injury and potentially other disorders, such as Parkinson’s disease and stroke. flyer actividad fisica